Twinbeech Capital LP Travere Therapeutics, Inc. Transaction History

Twinbeech Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.18 - $9.82 $42,067 - $57,535	-5,859 Reduced 28.47%	14,718 $113,000
Q4 2023 Feb 14, 2024	SELL	$5.44 - $9.5 $1.13 Million - $1.98 Million	-208,209 Reduced 91.01%	20,577 $184,000
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $435,021 - $982,215	56,940 Added 33.13%	228,786 $2.05 Million
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $600,035 - $886,718	39,218 Added 29.57%	171,846 $2.64 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $1.87 Million - $2.4 Million	104,855 Added 377.54%	132,628 $2.98 Million
Q4 2022 Feb 14, 2023	SELL	$18.47 - $26.14 $901,908 - $1.28 Million	-48,831 Reduced 63.74%	27,773 $584,000
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $1.75 Million - $2.19 Million	76,604 New	76,604 $1.89 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.